Browse the corpus

REFERENCES Aasebø W, Midtvedt K, Valderhaug TG, et al, “Impaired Glucose Homeostasis in Renal Transplant Recipients Receiving Basiliximab,” Nephrol Dial Transplant , 2010, 25(4):1289-93. [PubMed 19934089 ] Brennen DC, Daller JA, Lake KD, et al, “Rabbit Antithymocyte Globulin Versus Basiliximab in Renal Transplantation,” N Engl J Med , 2006, 355(19):1967-77. [PubMed 17093248 ] Kahan BD, Rajagopalan PR, and Hall M, “Reduction of the Occurrence of Acute Cellular Rejection Among Renal Allograft Recipients Treated With Basiliximab, a Chimeric Anti-Interleukin-2-Receptor Monoclonal Antibody. United States Simulect Renal Study Group,” Transplantation , 1999, 67(2):276-84. [PubMed 10075594 ] Mehra MR, Zucker MJ, Wagoner L, et al, “A Multicenter, Prospective, Randomized, Double-Blind Trial of Basiliximab in Heart Transplantation,” J Heart Lung Transplant , 2005, 24(9):1297-304. [PubMed 16143248 ] Nashan B, Moore R, Amlot P, et al, “Randomised Trial of Basiliximab Versus Placebo for Control of Acute Cellular Rejection in Renal Allograft Recipients,” Lancet , 1997, 350(9086):1193-8. [PubMed 9652559 ] Neuhaus P, Clavien PA, Kittur D, et al, “Improved Treatment Response With Basiliximab Immunoprophylaxis After Transplantation: Results From a Double-Blind Randomized Placebo-Controlled Trial,” Liver Transpl , 2002, 8(2):132-42. [PubMed 11862589 ] Offner G, Toenshoff B, Höcker B, et al, “Efficacy and Safety of Basiliximab in Pediatric Renal Transplant Patients Receiving Cyclosporine, Mycophenolate Mofetil, and Steroids,” Transplantation , 2008, 86(9):1241-8. [PubMed 19005406 ] Schmidt-Hieber M, Feitz T, Knauf W, et al, “Efficacy if the Interleukin-2 Receptor Antagonist Basiliximab in Steroid-Refractory Acute Graft-Versus-Host Disease, Br J Haematol , 2005, 130(4):568-74. [PubMed 16098072 ] Topic 8803 Version 40.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [0602-201.77.166.39-2E861B2D37-S244013.14]